Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | PDE8B | O95263 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19381825 | 1.00 | LMNA (0.52) | LMNATSHRALDH1A1CYP2C9CYP2D6 | |
| SCHEMBL15081949 | 0.82 | TSHR (0.44) | TSHRALDH1A1CYP2C9CYP2D6CYP3A4 | |
| SCHEMBL19368232 | 0.82 | TSHR (0.44) | TSHRALDH1A1CYP2C9CYP2D6CYP3A4 | |
| SCHEMBL14375259 | 0.81 | ALOX15 (0.52) | TSHRALDH1A1CYP2C9CYP2D6CYP3A4 | |
| SCHEMBL4487346 | 0.79 | ALOX15 (0.59) | TSHRALDH1A1CYP2C9CYP2D6CYP3A4 | |
| SCHEMBL807362 | 0.77 | ALOX15 (0.58) | TSHRALDH1A1CYP2C9CYP2D6CYP3A4 | |
| SCHEMBL28290484 | 0.77 | ALOX15 (0.51) | TSHRALDH1A1CYP2C9CYP2D6CYP3A4 | |
| SCHEMBL18709319 | 0.76 | ALOX15 (0.47) | TSHRALDH1A1CYP2C9CYP2D6CYP3A4 | |
| SCHEMBL28135479 | 0.76 | HRH3 (0.44) | TSHRALDH1A1CYP2C9ALOX15KDM4E | |
| SCHEMBL21579027 | 0.75 | LMNA (0.48) | LMNATSHRALDH1A1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242981-B2 | Fused pyrazole derivatives as novel ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MAPK1, MAPK3, MAP3K1 | LMNA 4751/4885TSHR 2368/4885ALDH1A1 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.